In the latest trading session, 0.4 million Novabay Pharmaceuticals Inc (AMEX:NBY) shares changed hands as the company’s beta touched 2.00. With the company’s most recent per share price at $0.13 changed hands at -$0.01 or -4.04% at last look, the market valuation stands at $3.93M. NBY’s current price is a discount, trading about -1400.0% off its 52-week high of $1.95. The share price had its 52-week low at $0.12, which suggests the last value was 7.69% up since then. When we look at Novabay Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 1.97 million shares, with the 3-month average coming to 3.33 million.
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
Instantly NBY was in red as seen in intraday trades today. With action -6.64%, the performance over the past five days has been red. The drop to weekly highs of 0.1450 subtracted -4.04% to the stock’s daily price. The company’s shares are showing year-to-date downside of -35.93%, with the 5-day performance at -6.64% in the red. However, in the 30-day time frame, Novabay Pharmaceuticals Inc (AMEX:NBY) is -15.13% down. Looking at the short shares, we see there were 0.27 million shares sold at short interest cover period of 0.05 days.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Data shows that the Novabay Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -72.04% over the past 6 months, a 74.85% in annual growth rate that is considerably higher than the industry average of 10.40%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Novabay Pharmaceuticals Inc will rise 61.50%, while the growth in revenue is estimated to hit 76.50% for the next quarter.
Consensus estimates given by 1 financial analysts project the company’s revenue in the current quarter to hit an average of $3.4 million. 1 analysts are of the opinion that Novabay Pharmaceuticals Inc’s revenue for the quarter ending Mar 2024 will be $4 million. The company’s revenue for the corresponding quarters a year ago was $3.64 million and $3.2 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.70%. The estimates for the next quarter sales put growth at 25.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 9.67%. The 2024 estimates are for Novabay Pharmaceuticals Inc earnings to increase by 77.13%.
NBY Dividends
Novabay Pharmaceuticals Inc is expected to release its next quarterly earnings report between March 28 and April 01.
Novabay Pharmaceuticals Inc (AMEX:NBY)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.44% of Novabay Pharmaceuticals Inc shares while 18.21% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 18.67%. There are 18.21% institutions holding the Novabay Pharmaceuticals Inc stock share, with Armistice Capital, LLC the top institutional holder. As of Dec 30, 2023, the company held 11.01% of the shares, roughly 0.72 million NBY shares worth $94086.0.
Renaissance Technologies, LLC holds the second largest percentage of outstanding shares, with 2.38% or 0.16 million shares worth $20357.0 as of Dec 30, 2023.
Among Mutual Funds, the top two as of Jan 30, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. With 23861.0 shares estimated at $3123.0 under it, the former controlled 0.37% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.21% of the shares, roughly 13710.0 shares worth around $1794.0.
